IceCure Medical Ltd. (ICCM) is an Israel-based company that is reshaping the future of minimally invasive treatments for benign and early-stage malignant tumors. Operating since 2006, IceCure is committed to developing and marketing cryoablation therapies that provide a simple, safe, and cost-effective solution for the treatment of tumors.
The flagship product of IceCure is its ProSense® System, a cryoablation device utilizing extremely cold temperatures to destroy tumors. The ProSense® System uses innovative, proprietary technology that enables high-level precision for tumor treatment while minimizing potential damage to surrounding healthy tissue. Its powerful and versatile approach is applicable to a broad range of tumors, making it an attractive option for healthcare providers.
This revolutionary product has gained regulatory approval under the Food and Drug Administration (FDA) for use in the US and CE Mark approval for use in the European Union. It has also been recognized by leading healthcare providers for delivering efficient treatments with minimal recovery times and lower recurrence rates compared to traditional surgical methods.
IceCure’s mission expands beyond just product development. The company places a strong emphasis on increasing awareness and recognition of cryoablation as an effective treatment for benign and malignant tumors. To accomplish this, IceCure actively participates in clinical research and collaborates with leading medical institutions around the world to continuously refine and enhance their products’ effectiveness.
The company's commitment to innovation, safety, and improving patient quality of life have established their position in the global cryoablation market. IceCure Medical is a public company listed on the Tel Aviv Stock Exchange (TASE: ICCM). Its growing success is largely accredited to its driven team of professionals who are dedicated to transforming the oncology field by simplifying tumor treatments and offering a gentler alternative to surgery.
Investors, healthcare providers, and patients alike have recognized IceCure Medical's potential. With their groundbreaking ProSense® System and a steadfast commitment to the development of cryoablation therapies, IceCure Medical Ltd. is revolutionizing the future of minimally invasive tumor treatments.